Tag: Thubrikar Aortic Valve

Thubrikar Aortic Valve Announces Clinical Success of the New Precision 2™ Delivery Catheter

COLLEGEVILLE, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc. today announced successful results in the first two patients implanted with the Optimum Transcatheter Aortic Valve (Optimum TAV™) using the new Precision 2™ Delivery Catheter. Interventional Cardiologist and TAVI-1 Study Principal Investigator, Jaroslaw Trebacz, […]

Thubrikar Aortic Valve to Present Promising Initial Results of CE Mark-Enabling Study With Novel Optimum TAV™ at EuroPCR 2023

NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., is happy to announce that results of the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in patients with severe aortic stenosis will be presented at the upcoming EuroPCR 2023 […]

Thubrikar Aortic Valve announces initial 30-day outcomes of CE Mark-enabling TAVI-1 Study

NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., announced today successful 30-day outcomes in the first two patients receiving the Optimum Transcatheter Aortic Valve (Optimum TAV™). The implantations were performed by the Principal Investigator, Jaroslaw Trebacz, MD, at the Specialty Hospital Jana […]